FDA Cites Reduced Surgery Burden in Inovio Accelerated Approval

Share

FDA concluded that Inovio Pharmaceuticals' Voceryq (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) offers a meaningful therapeutic benefit over an existing treatment for recurrent respiratory papillomatosis (RRP) because it requires fewer surgical procedures, despite the absence of direct comparative efficacy data, according to a newly available agency review.

The just-posted 23-page Summary Basis for Regulatory Action explains FDA's decision to grant accelerated approval to Voceryq for reducing surgical papilloma excisions in adults with RRP, a rare disease associated with recurrent growths in the respiratory tract.

FDA compared Voceryq with Precigen’s Papzimeos, approved in 2025, noting that Papzimeos requires surgical removal of visible papillomas with the first, third and fourth doses, while Voceryq requires surgery only with the initial dose.

Although no head-to-head data establish comparative efficacy, FDA determined that the reduced surgical burden offers therapeutic and public health benefits by limiting risks of airway scarring, stenosis and other complications associated with repeated procedures.

The accelerated approval was supported by the single-arm, open-label Phase 1/2 RRP-001 trial (NCT04398433), which enrolled 32 patients. Among 26 patients in the primary efficacy population, seven (27%) required no clinically indicated papilloma excisions during the 12 months following treatment. The mean reduction was 1.4 surgical procedures per year.

As part of the approval, FDA also required six chemistry, manufacturing and controls commitments and two device-related commitments addressing potency assay validation, manufacturing comparability, product specifications, container-closure integrity, human-factors evaluation and reliability of the electroporation delivery device's sharps safety feature.

Additionally, a separate confirmatory clinical trial must evaluate the durability of treatment benefit and symptom improvement in adults and children with RRP over at least three years of follow-up. The final study report is due in 2032.

FDA concluded that the available clinical and manufacturing evidence supported approval, while acknowledging limitations associated with the small, uncontrolled clinical study.

Read more